ARTG 296368Diabetes patient management software
ARTG ID: 296368 · Ypsomed Australia Pty Ltd · SINOVO health solutions GmbH · Class IIb · Started November 16, 2017
Good Name: Ypsomed Australia Pty Ltd - Diabetes patient management software
- Risk Class
- Class IIb
- Product Type
- Single Device Product
- ARTG Category
- General
- ARTG ID
- 296368
- Start Date
- November 16, 2017
- Effective Date
- November 16, 2017
- Country
- Germany
- Address
- Willy-Brandt-Strasse 4, Bad Vilbel, 61118
The mylife App is intended to be used by persons with diabetes and/or their caregivers. The mylife App is an application for smartphones that allows you to log therapy data and calculate bolus suggestions for delivery. In addition, data can be read from the mylife YpsoPump as well as from the connectable devices such as the mylife Unio Neva and mylife Aveo blood glucose meters and the Dexcom G6 CGM system via their Bluetooth interfaces. Logged therapy data like carbohydrate estimates, blood glucose measurements and real-time Dexcom G6 CGM data may be used for therapy decisions supported by the mylife App. The mylife™ App is able to initiate boluses on the mylife™ Ypsopump® (selected pump versions).
Access comprehensive regulatory information for Diabetes patient management software in the Australia medical device market through Pure Global AI's free TGA ARTG database. This Class IIb is registered under ARTG number 296368 and sponsored by Ypsomed Australia Pty Ltd, manufactured by SINOVO health solutions GmbH in Germany. The device registration started on November 16, 2017.
This page provides complete registration details including sponsor information, manufacturer details, and regulatory compliance data from the official Australia TGA ARTG medical device database. Pure Global AI offers free access to Australia's complete medical device registry with 131,000+ devices, helping global MedTech companies navigate TGA regulations efficiently.